Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (EFficacy of FOSAMAX versus EVISTAComparison Trial) International.

摘要

Abstract. Sambrook PN, Geusens P, Ribot C, Solimano JA, Ferrer-Barriendos J, Gaines K, Verbruggen N, Melton ME (University of Sydney, Sydney, Australia; University Campus Limburg, Diepenbeek, Belgium; University Hospital, Maastricht, The Netherlands; CHU Toulouse Hopital de Rangueil, Toulouse, France; Instituto Medico Miraflores, Lima, Peru; Hospital Universitario Central de Asturias, Oviedo, Spain; and Merck & Co., Inc., Whitehouse Station, NJ, USA). Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (EFficacy of FOSAMAX((R)) versus EVISTA((R))Comparison Trial) International. J Intern Med 2004; 255: 503-511.Objectives. Alendronate and raloxifene are antiresorptive agents with different mechanisms of action, each used to treat osteoporosis in postmenopausal women. This study was undertaken to compare the efficacy and tolerability of alendronate to raloxifene in postmenopausal women with low-bone density. Design. Randomized, double-masked, double-dummy multicentre international study. Setting. Clinical trial centres in Europe, South America and Asia-Pacific. Subjects. A total of 487 postmenopausal women with low bone density, based on bone mineral density (BMD) of the lumbar spine or hip (T-score